Taken together, our study suggests that the combined targeted inhibition of STAT1, ARTD8, ARTD9 and/or DTX3L could increase the efficacy of chemotherapy or radiation treatment in prostate and other high-risk tumor types with an increased STAT1- and STAT3-signaling. The gene discussed is DTX3L; the disease is neoplasm.